Relevant bibliographies by topics / Bacteria in cancer therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Bacteria in cancer therapy'

Author: Grafiati
Published: 14 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Bacteria in cancer therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Bacteria in cancer therapy"

1

Duong, Mai Thi-Quynh, Yeshan Qin, Sung-Hwan You, and Jung-Joon Min. "Bacteria-cancer interactions: bacteria-based cancer therapy." Experimental & Molecular Medicine 51, no. 12 (December 2019): 1–15. http://dx.doi.org/10.1038/s12276-019-0297-0.

Full text
Abstract:
AbstractRecent advances in cancer therapeutics, such as targeted therapy and immunotherapy, have raised the hope for cures for many cancer types. However, there are still ongoing challenges to the pursuit of novel therapeutic approaches, including high toxicity to normal tissue and cells, difficulties in treating deep tumor tissue, and the possibility of drug resistance in tumor cells. The use of live tumor-targeting bacteria provides a unique therapeutic option that meets these challenges. Compared with most other therapeutics, tumor-targeting bacteria have versatile capabilities for suppressing cancer. Bacteria preferentially accumulate and proliferate within tumors, where they can initiate antitumor immune responses. Bacteria can be further programmed via simple genetic manipulation or sophisticated synthetic bioengineering to produce and deliver anticancer agents based on clinical needs. Therapeutic approaches using live tumor-targeting bacteria can be applied either as a monotherapy or in combination with other anticancer therapies to achieve better clinical outcomes. In this review, we introduce and summarize the potential benefits and challenges of this anticancer approach. We further discuss how live bacteria interact with tumor microenvironments to induce tumor regression. We also provide examples of different methods for engineering bacteria to improve efficacy and safety. Finally, we introduce past and ongoing clinical trials involving tumor-targeting bacteria.
APA, Harvard, Vancouver, ISO, and other styles
2

Yaghoubi, Atieh, Majid Khazaei, Seyed Mahdi Hasanian, Amir Avan, William C. Cho, and Saman Soleimanpour. "Bacteriotherapy in Breast Cancer." International Journal of Molecular Sciences 20, no. 23 (November 23, 2019): 5880. http://dx.doi.org/10.3390/ijms20235880.

Full text
Abstract:
Breast cancer is the second most common cause of cancer-related mortality among women around the world. Conventional treatments in the fight against breast cancer, such as chemotherapy, are being challenged regarding their effectiveness. Thus, strategies for the treatment of breast cancer need to be continuously refined to achieve a better patient outcome. We know that a number of bacteria are pathogenic and some are even associated with tumor development, however, recent studies have demonstrated interesting results suggesting some bacteria may have potential for cancer therapy. Therefore, the therapeutic role of bacteria has aroused attention in medical and pharmaceutical studies. Furthermore, genetic engineering has been used in bacterial therapy and may led to greater efficacy with few side effects. Some genetically modified non-pathogenic bacterial species are more successful due to their selectivity for cancer cells but with low toxicity for normal cells. Some live, attenuated, or genetically modified bacterias are capable to multiply in tumors and inhibit their growth. This article aims to review the role of bacteria and their products including bacterial peptides, bacteriocins, and toxins for the treatment of breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
3

Harimoto, Tetsuhiro, and Tal Danino. "Engineering bacteria for cancer therapy." Emerging Topics in Life Sciences 3, no. 5 (October 11, 2019): 623–29. http://dx.doi.org/10.1042/etls20190096.

Full text
Abstract:
The engineering of living cells and microbes is ushering in a new era of cancer therapy. Due to recent microbiome studies indicating the prevalence of bacteria within the human body and specifically in tumor tissue, bacteria have generated significant interest as potential targets for cancer therapy. Notably, a multitude of empirical studies over the past decades have demonstrated that administered bacteria home and grow in tumors due to reduced immune surveillance of tumor necrotic cores. Given their specificity for tumors, bacteria present a unique opportunity to be engineered as intelligent delivery vehicles for cancer therapy with synthetic biology techniques. In this review, we discuss the history, current state, and future challenges associated with using bacteria as a cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
4

Mathuriya, Abhilasha S. "Magnetotactic bacteria for cancer therapy." Biotechnology Letters 37, no. 3 (November 12, 2014): 491–98. http://dx.doi.org/10.1007/s10529-014-1728-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dougan, Michael, and Stephanie K. Dougan. "Programmable bacteria as cancer therapy." Nature Medicine 25, no. 7 (July 2019): 1030–31. http://dx.doi.org/10.1038/s41591-019-0513-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fdez-Gubieda, M. L., J. Alonso, A. García-Prieto, A. García-Arribas, L. Fernández Barquín, and A. Muela. "Magnetotactic bacteria for cancer therapy." Journal of Applied Physics 128, no. 7 (August 21, 2020): 070902. http://dx.doi.org/10.1063/5.0018036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Darmov, I. V., Ya A. Kibirev, I. V. Marakulin, and S. N. Yanov. "USE OF BACTERIA IN CANCER THERAPY (REVIEW)." Russian Journal of Biotherapy 18, no. 4 (December 2, 2019): 34–42. http://dx.doi.org/10.17650/1726-9784-2019-18-4-34-42.

Full text
Abstract:
Bacterial drugs for the treatment of malignant tumors have been discovered more than a hundred years ago, but their use in clinical practice has been very limited. In the past decade, there has been a revival of interest in the development of bacterial-based cancer biotherapies, which is associated with advances in genetic engineering and in depth knowledge of the mechanisms of the infectious process and immunity. The purpose of this review is to examine the current state and prospects for the development and use of drugs based on live bacterium, intended for the treatment of malignant tumors. The review presents evaluation data on experimental models of the antitumor potential of various species and strains of bacteria; the most significant results of clinical trials of bacterial antitumor agents; current trends in the design of bacterial strains for targeted drug delivery to the tumor. It is concluded that development of bacterial drugs for cancer therapy is a perspective branch of experimental oncology.
APA, Harvard, Vancouver, ISO, and other styles
8

Yoon, Wonsuck, Yongsung Park, Seunghyun Kim, Yongkeun Park, and Chul Yong Kim. "Combined Therapy with microRNA-Expressing Salmonella and Irradiation in Melanoma." Microorganisms 9, no. 11 (November 22, 2021): 2408. http://dx.doi.org/10.3390/microorganisms9112408.

Full text
Abstract:
Anticancer treatment strategies using bacteria as a vector are currently expanding with the development of anticancer drugs. Here, we present a research strategy to develop anticancer drugs using bacteria that contain miRNAs. We also present a strategy for the development of novel bacterial anticancer drugs in combination with radiation. Salmonella strains expressing miRNA were produced by modifying the miRNA expression vector encoding INHA, a radiation-resistant gene developed previously. The anticancer effect of INHA was confirmed using skin cancer cell lines. We also tested a combination strategy comprising bacteria and radiation for its anticancer efficacy against radiation-resistant mouse melanoma to increase the efficacy of radiation therapy as a novel strategy. The recombinant strain was confirmed to promote effective cell death even when combined with radiation therapy, which exerts its cytotoxicity by enhancing reactive oxygen species production. Moreover, a combination of bacterial and radiation therapy enhanced radiotherapy efficacy. When combined with radiation therapy, bacterial therapy exhibited effective anti-cancer properties even when administered to animals harboring radiation-resistant tumors. This strategy may promote the secretion of cytokines in cells and more effectively reduce the number of bacteria remaining in the animal. Thus, this study may lead to the development of a strategy to improve the effectiveness of radiation therapy using Salmonella expressing cancer-specific miRNA for intractable cancers such as those resistant to radiation.
APA, Harvard, Vancouver, ISO, and other styles
9

Gupta, Kajal H., Christina Nowicki, Eileena F. Giurini, Amanda L. Marzo, and Andrew Zloza. "Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy." Vaccines 9, no. 12 (December 18, 2021): 1497. http://dx.doi.org/10.3390/vaccines9121497.

Full text
Abstract:
Currently approximately 10 million people die each year due to cancer, and cancer is the cause of every sixth death worldwide. Tremendous efforts and progress have been made towards finding a cure for cancer. However, numerous challenges have been faced due to adverse effects of chemotherapy, radiotherapy, and alternative cancer therapies, including toxicity to non-cancerous cells, the inability of drugs to reach deep tumor tissue, and the persistent problem of increasing drug resistance in tumor cells. These challenges have increased the demand for the development of alternative approaches with greater selectivity and effectiveness against tumor cells. Cancer immunotherapy has made significant advancements towards eliminating cancer. Our understanding of cancer-directed immune responses and the mechanisms through which immune cells invade tumors have extensively helped us in the development of new therapies. Among immunotherapies, the application of bacteria and bacterial-based products has promising potential to be used as treatments that combat cancer. Bacterial targeting of tumors has been developed as a unique therapeutic option that meets the ongoing challenges of cancer treatment. In comparison with other cancer therapeutics, bacterial-based therapies have capabilities for suppressing cancer. Bacteria are known to accumulate and proliferate in the tumor microenvironment and initiate antitumor immune responses. We are currently well-informed regarding various methods by which bacteria can be manipulated by simple genetic engineering or synthetic bioengineering to induce the production of anti-cancer drugs. Further, bacterial-based cancer therapy (BBCT) can be either used as a monotherapy or in combination with other anticancer therapies for better clinical outcomes. Here, we review recent advances, current challenges, and prospects of bacteria and bacterial products in the development of BBCTs.
APA, Harvard, Vancouver, ISO, and other styles
10

Yoo, Su Woong, Dinh-huy Nguyen, Suhyeon Park, Hyeri Lee, Chang-Moon Lee, Changho Lee, and Jung-Joon Min. "Development of Dual-Scale Fluorescence Endoscopy for In Vivo Bacteria Imaging in an Orthotopic Mouse Colon Tumor Model." Applied Sciences 10, no. 3 (January 24, 2020): 844. http://dx.doi.org/10.3390/app10030844.

Full text
Abstract:
Colorectal cancer is a representative cancer where early diagnosis and proper treatment monitoring are important. Recently, cancer treatment using bacteria has actively progressed and has been successfully monitored using fluorescence imaging techniques. However, because subcutaneous tumor models are limited in reflecting the actual colorectal cancer situation, new imaging approaches are needed to observe cancers growing in the colon. The fluorescence endoscopic approach is an optimal monitoring modality to evaluate the therapeutic response of bacteria in orthotopic colon cancer. In this study, we developed dual-scaled fluorescence endoscopy (DSFE) by combining wide-field fluorescence endoscopy (WFE) and confocal fluorescence endomicroscopy (CFEM) and demonstrated its usefulness for evaluating bacterial therapy. Firstly, the endoscopic probe of DSFE was developed by integrating the CFEM probe into the guide sheath of WFE. Secondly, colorectal cancer tumor growth and tumors infiltrating the fluorescent bacteria were successfully monitored at the multi-scale using DSFE. Finally, the bacterial distribution of the tumor and organs were imaged and quantitatively analyzed using CFEM. DSFE successfully exhibited fluorescent bacterial signals in an orthotopic mouse colon tumor model. Thus, it can be concluded that the DSFE system is a promising modality to monitor bacterial therapy in vivo.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Bacteria in cancer therapy"

1

Cao, Siyu. "Designer bacteria as anti-cancer agents." Thesis, Griffith University, 2013. http://hdl.handle.net/10072/366498.

Full text
Abstract:
To date, cancer persists as one of the most devastating diseases worldwide. Problems such as inoperable primary tumours due to late stage diagnosis, presence of metastatic tumours, and tumour resistance to chemotherapy and radiotherapy have remarkably limited the therapeutic effects of existing treatments. To address these problems, cancer gene therapy has been under rapid development over the past two decades, which is specifically designed to deliver therapeutic genes to treat cancers using vector systems. However, the lack of an ideal vector has been a major drawback. Recent understanding of hypoxic and necrotic regions within solid malignancies and rapid development of recombinant DNA technology have reignited the idea of using anaerobic bacteria such as Clostridium as novel intra-tumoural delivery systems for anti-cancer therapeutics. These bacterial vectors have unique advantages over other delivery systems and are likely to become the vector of choice for cancer therapy in the near future. At present, Clostridium-mediated cancer therapy has shown some promising therapeutic efficacy against a number of solid malignancies, providing an opportunity for the development of novel anti-cancer gene therapies. In the last decade, targeted cancer therapy has witnessed its most impressive progress. Anti-cancer monoclonal antibodies (mAb) and recombinant immunotoxins against specific tumour cell surface antigens such as epidermal growth factor receptor (EGFR) have shown encouraging therapeutic efficacy against a large spectrum of cancers. However, difficulties such as insufficient intra-tumoural drug delivery have been preventing the therapy from reaching its full therapeutic potentials.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Medical Science
Griffith Health
Full Text
APA, Harvard, Vancouver, ISO, and other styles
2

Traore, Mahama Aziz. "Bacteria-Enabled Autonomous Drug Delivery Systems: Design, Modeling, and Characterization of Transport and Sensing." Diss., Virginia Tech, 2014. http://hdl.handle.net/10919/64326.

Full text
Abstract:
The lack of efficacy of existing chemotherapeutic treatments of solid tumors is partially attributed to the limited diffusion distance of therapeutics and the low selectivity of anti-cancer drugs with respect to cancerous tissue, which also leads to high levels of systemic toxicity in patients. Thus, chemotherapy can be enhanced through improving anti-cancer drug carrier selectivity and transport properties. Several strains of gram positive (e.g. Clostridium and Bifidobacterium) and gram-negative (e.g. Salmonella Typhimurium and Escherichia coli) bacteria have been shown to possess the innate ability to preferentially colonize tumor tissues. The overall goal of this dissertation is to characterize the transport and sensing of Bacteria-Enabled Drug Delivery Systems (BEADS) in select relevant environments and to investigate the associated underlying principles. BEADS consist of an engineered abiotic load (i.e. drug-laden micro or nano-particles) and a living component (i.e. bacteria) for sensing and actuation purposes. Findings of this dissertation work are culminated in experimental demonstration of deeper penetration of the NanoBEADS within tumor tissue when compared to passively diffusing chemotherapeutic nanoparticles. Lastly, the transport mechanisms that Salmonella Typhimurium VNP20009 utilize to preferentially colonize solid tumors are also examined with the ultimate goal of engineering intelligent and more efficacious drug delivery vehicles for cancer therapy.
Ph. D.
APA, Harvard, Vancouver, ISO, and other styles
3

LEPORI, IRENE. "Optimization of attenuated Listeria monocytogenes cell wall chemical engineering to increase its anticancer vaccine activity and to use it as metastasis tracer." Doctoral thesis, Università di Siena, 2019. http://hdl.handle.net/11365/1072153.

Full text
Abstract:
Attenuated Listeria monocytogenes (Lmat) is widely investigated as anticancer vaccine thanks to its capability to activate host immune-response against the tumour tissues. Lots of genetic engineering strategies have been used to improve its power, such as increasing its immune-stimulation against the cancer tissues by the expression of tumour associated antigens. Since Lmat is capable to selectively accumulate in primary tumours and metastasis, compared with the healthy tissues, we started exploring the possibility of using Lmat as drug carrier and metastasis tracer, by using chemical cell wall modifications that allow us to attach little chemicals onto the bacterial cell wall. In this work we optimized the chemical engineering of Lmat cell wall to let it expose reporter chemical groups, such as alkyne or azido group, that can selectively react with the respective chemical partner (azido and alkyne) by bioorthogonal and bio-compatible “click-reaction”. After comparison of different probes for the functionalization of Lmat cell wall, we optimized the protocol for efficient and totally bio-compatible labelling by using azido-D-alanine probe and both the strain-promoted alkyne-azide cycloaddition (SPAAC) and the copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) reactions. We tested the in vitro features of labelled Lmat and demonstrated that it maintains unaltered proliferative activity, infectivity and intrinsic toxicity effect on 501-mel cell line. We started exploring the chemical conjugation between Lmat and doxorubicin for the drug-carrier strategy, and with Cy7.5 Photoacoustic Dye (PAI) for the metastasis imaging strategy.
APA, Harvard, Vancouver, ISO, and other styles
4

Kandoth, Noufal. "Design, Synthesis and Characterization of Photoactivable Cyclodextrin-Based Nanoparticles for Multimodal Anticancer Therapy." Doctoral thesis, Università di Catania, 2013. http://hdl.handle.net/10761/1280.

Full text
Abstract:
Abstract The general goal of this thesis is the development of new generation photoactivable smart nanomaterials that can be modulated into tremendous way to achieve multimodal anticancer and antimicrobial therapeutic actions. Here the cyclodextrins act as the building block for the development of the nanocarrier in order to convey the therapeutic payload to the desired site. With this goal in mind, we have developed several kinds of nanosystems and are discussed in each chapter. The entire dissertation is divided into four sections based on the types of materials and the sections are further divided into twelve chapters based on the functional behavior of each nanosystems.
APA, Harvard, Vancouver, ISO, and other styles
5

Babatunde, Oluwaseun Oyeniyi. "Exploring the potential of Rhodobacter sphaeroides in photodynamic therapy of tumors." Bowling Green State University / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=bgsu1624793446693196.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Babatunde, Oluwaseun Oyeniyi. "Exploring the potential of Rhodobacter sphaeroides in photodynamic therapy of tumors." Bowling Green State University / OhioLINK, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=bgsu1624793446693196.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pahle, Jessica. "Oncoleaking gene therapy: a new suicide approach for treatment of pancreatic cancer." Doctoral thesis, Humboldt-Universität zu Berlin, 2018. http://dx.doi.org/10.18452/19298.

Full text
Abstract:
Bakterielle Toxine stellen eine wirkungsvolle und effektive Alternative zur Therapie von Tumorerkrankungen dar. Das vom Clostridium perfringens Typ A produzierte Clostridium perfringens enterotoxin (CPE) gehört zu der Gruppe der porenbildenden Toxine und weist eine rezeptorspezifische zytotoxische Wirkung auf, welche über die Membranrezeptoren Cldn3 und Cldn4 entfaltet wird. Diese liegen vor allem in Epithelialkarzinomen wie dem Brust-, Prostata-, oder Kolon-, sowie dem Pankreaskarzinom (PK) stark hochreguliert vor. Ziel dieser Arbeit war die Anwendung des neuen selektiven und effizienten „Onkoleaking“ Suizid-Gentherapie Konzepts für die Behandlung von Cldn3 / 4 überexprimierender PK unter Verwendung eines nicht-viralen translations-optimierten CPE exprimierenden Vektors (optCPE). Weiterhin sollte in dieser Arbeit der genaue molekulare Mechanismus der CPE-vermittelten Zytotoxizität in vitro und auch in vivo analysiert werden. Für die in vitro Analysen wurden verschiedene humane PK Zelllinien, Patienten abgeleitete Xenotransplantate (PDX) und deren abgeleiteten Zellen bezüglich ihrer Cldn3 / 4 Expression und Sensitivität sowohl gegenüber rekombinantem CPE (rekCPE) als auch nach optCPE Gentransfer untersucht. Es konnte eine positive Korrelation zwischen der Effizienz CPE vermittelter Zytotoxizität und der Höhe der Cldn3 / 4 Überexpression gezeigt werden. Des Weiteren wurde die Verfügbarkeit und Zugänglichkeit der CPE Rezeptoren für die Toxinbindung als kritischer Faktor für die durch Porenbildung induzierte Zytotoxizität beschrieben. Auch eine detaillierte Analyse verschiedener apoptotischer und nekrotischer Signalwege und deren Schlüsselmoleküle waren vom besonderen Interesse. Von noch größerer Wichtigkeit war jedoch die Anwendbarkeit und der Nachweis der antitumoralen Wirksamkeit der optCPE-basierten Suizid-Gentherapie mit Hilfe des intratumoralen Jet-Injektion Gentransfers in verschiedenen Luziferase-exprimierenden CDX und PDX Modellen des PK. Alle in vivo Studien zeigten eine selektive optCPE vermittelte Verminderung der Tumorvitalität in Verbindung mit Nekrose, die in fast allen Fällen mit einer Reduktion des Tumorvolumens einher ging. Die tierexperimentellen Studien belegen damit die Effektivität der CPE-basierten Gentherapie im Pankreaskarzinom. Mit diesen neu gewonnenen Erkenntnissen zum „Onkoleaking“ Konzept der CPE Suizid-Gentherapie und deren Wirkungsmechanismen sind Kombinationen mit konventionellen Therapien möglich.
Bacterial toxins have evolved to an effective therapeutic option for cancer therapy and numerous studies demonstrated their antitumoral potential. The Clostridium perfringens enterotoxin (CPE), produced by the anaerobic Clostridium perfringes bacteria, is a pore-forming (oncoleaking) toxin, which binds to its receptors claudin-3 and -4 (Cldn3 / 4) and exerts a selective, receptor-dependent cytotoxicity. The transmembrane tight junction proteins Cldn3 and Cldn4 are known CPE receptors and are highly upregulated in several human epithelial cancers such as breast, colon, ovarian and pancreatic cancer. This study aimed at the evaluation of the potential of oncoleaking gene therapy using a non-viral translation optimized CPE vector (optCPE) as a new suicide approach for the treatment of Cldn3  /  4 overexpressing pancreatic cancer (PC) in vitro and in vivo. We demonstrated the successful in vitro use of optCPE gene transfer in a panel of human PC cells and more importantly patient derived PC xenograft (PDX) derived cells. We showed significant reduction of cell viability in all Cldn3 / 4 overexpressing PC cells after optCPE transfection. Furthermore a positive correlation between CPE cytotoxicity and level of claudin expression was shown. We revealed accessibility of CPE receptors for toxin binding as determining for optCPE mediated cytotoxicity. Since investigation of optCPE induced cell death mechanism was of particular interest, detailed analyses of apoptotic and necrotic key players were performed. By this, caspase dependent- and independent apoptosis and necrosis activation after gene transfer was demonstrated, which was dependent on amount of expressed optCPE and accessibility of Cldn. More importantly, this study demonstrated the applicability and antitumoral efficacy of optCPE gene therapy by the non-viral intratumoral jet-injection gene transfer in vivo in different luciferase-expressing CDX and PDX pancreatic cancer models. The animal experiments demonstrated the selective CPE mediated tumor growth inhibition, associated with reduced tumor viability and effective induction of tumor necrosis. This further corroborated the advantages of this novel oncoleaking strategy. With this gain of knowledge about our new oncoleaking concept of suicidal gene therapy and its mechanism of action, novel combinations with conventional therapies are possible to further improve therapeutic efficacy and to overcome resistance in pancreas carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
8

Broadway, Katherine Marie. "Novel Perspectives on the Utilization of Chemotactic Salmonella Typhimurium VNP20009 as an Anticancer Agent." Diss., Virginia Tech, 2018. http://hdl.handle.net/10919/84898.

Full text
Abstract:
Attenuated bacterial strains have been investigated on the premise of selective tumor colonization and drug delivery potential for decades. Salmonella Typhimurium VNP20009 was derived from the parental strain 14028 through genetic modification and tumor targeting ability, being well studied for anticancer effects in mice. In 2001 Phase 1 Clinical Trials, patients diagnosed with melanoma were introduced with VNP20009, resulting in safe delivery of the strain and targeting to the tumor, however no anticancer effects were observed. Recently, it was discovered that VNP20009 contains a SNP in cheY, which encodes the chemotaxis response regulator of flagellar motor function, rendering the strain deficient in chemotaxis. Replacement of cheY with the 14028 wild-type copy resulted in a 70% restoration of phenotype in traditional chemotaxis capillary assays compared to the parental strain. We attempted to optimize the chemotactic potential of VNP20009 but were unable without reversing the attenuated state of VNP20009. Due to the role of chemotaxis in bacterial tumor colonization and eradication remaining unclear, we aimed to compare VNP20009 and VNP20009 cheY+ primary tumor colonization and impact on metastasis in an aggressive 4T1 mouse mammary carcinoma model. Bacterial tumor colonization and metastatic potential of the cancerous cells to the lungs appear bacterial chemotaxis independent. Moreover, mice bearing tumors exposed to Salmonella exhibited increased morbidity that was associated with significant liver disease. Our results suggest that in our timeline VNP20009 may not be safe or efficacious when used in the context of immunocompetent animals with aggressive, metastatic breast cancer. In a novel approach, we aimed to understand the bacterial-cancer cell relationship within the tumor microenvironment, with an emphasis on gene expression changes occurring within the eukaryotic transcriptome. We employed the B16-F10 mouse melanoma model because VNP20009 is known to colonize and eradicate these tumors in mice. First, we optimized a timeline for Salmonella treatment of mouse melanoma, finding a dramatic delay in tumor growth between 2 and 7 days due to the presence of Salmonella. Additionally, we observed upregulation of the IFN-gamma signaling pathway within tumor tissue upon exposure to Salmonella after 7 days. In future studies, we aim to analyze the bacterial transcriptome in the tumor microenvironment to gain unique understanding and contribute to knowledge supporting bacterial-mediated cancer therapies.
Ph. D.
APA, Harvard, Vancouver, ISO, and other styles
9

Liu, Ping. "Structural, Kinetic and Mutational Analysis of Two Bacterial Carboxylesterases." Digital Archive @ GSU, 2007. http://digitalarchive.gsu.edu/biology_diss/26.

Full text
Abstract:
The crystal structures of two thermostable carboxylesterase Est30 and Est55 from Geobacillus stearothermophilus were determined to help understand their functions and applications in industry or medicine. The crystal structure of Est30 was determined at 1.63 Å resolution by the multiple anomalous dispersion method. The two-domain Est30 structure showed a large domain with a modified alpha/beta hydrolase core including a seven, rather than an eight-stranded beta sheet, and a smaller cap domain comprising three alpha helices. A 100 Da tetrahedral ligand, propyl acetate, was observed to be covalently bound to the side chain of Ser94 in the catalytic triad. This ligand complex represents the first tetrahedral intermediate in the reaction mechanism. Therefore, this Est30 crystal structure will help understand the mode of action of all enzymes in the serine hydrolase superfamily. Est55 is a bacterial homologue of the mammalian carboxylesterases involved in hydrolysis and detoxification of numerous peptides and drugs and in prodrug activation. Est55 crystals were grown at pH 6.2 and pH 6.8 and the structures were determined at resolutions of 2.0 and 1.58 Å respectively. Est55 folds into three domains, a catalytic domain, an α/β domain and a regulatory domain. This structure is in an inactive form; the side chain of His409, one of the catalytic triad residues, is pointing away from the active site. Moreover, the adjacent Cys408 is triply oxidized and lies in the oxyanion hole, which would block the entry of substrate to its binding site. This structure suggested a self-inactivation mechanism, however, Cys408 is not essential for enzyme activity. Mutation of Cys408 showed that hydrophobic side chains at this position were favorable, while polar serine was unfavorable for enzyme activity. Both Est30 and Est55 were shown to hydrolyze the prodrug CPT-11 into the active form SN-38. Therefore, Est30 and Est55 are potential candidates for use with irinotecan in cancer therapy. The catalytic efficiency (kcat/Km) of Est30 is about 10-fold lower than that of Est55. The effects of the Cys408 substitutions on Est55 activity differed for the two substrates, p-NP butyrate and CPT-11. Mutant C408V may provide a more stable form of Est55.
APA, Harvard, Vancouver, ISO, and other styles
10

Almeida, Joana Raquel Santos Leite. "Multidrug resistant bacteria inactivation by photodynamic therapy." Master's thesis, Universidade de Aveiro, 2011. http://hdl.handle.net/10773/7295.

Full text
Abstract:
Mestrado em Biologia Aplicada - Microbiologia Clínica e Ambiental
The development of antimicrobials promoted the idea that diseases provoked by microorganisms would diminish and would be reduced to the insignificancy to human health. However, the great amount of antibiotics used in human medicine and veterinary lead to a selection of pathogenic bacteria resistant to multiple antibiotics, being hospital wastewaters one of the most important sources of antibiotic-resistant organisms and antibiotic-resistance genes that are released into the environment. The significant increase in the development of multiple resistance mechanisms to antibiotics caused an increase in the research of alternative treatments that may be cost effective and human friendly. Antimicrobial photodynamic therapy (aPDT) is a quickly expanding technology for the treatment of diseases since it inactivates efficiently microorganisms, is cost effective and human safe. The general objective of this work was to assess the inactivation of 4 clinical multidrug-resistant bacteria by aPDT, using a tetracationic porphyrin (PS). The efficacy of aPDT was assessed in phosphate buffered saline (PBS) and in hospital residual water for each isolated bacterium and for the bacteria mixtured all together. The synergistic effect of aPDT and antibiotics (ampicillin and chloramphenicol) was also evaluated as well as the effect of sodium dodecylsulphate (SDS) on aPDT efficiency. The results show an efficient inactivation of multidrug-resistant bacteria in PBS using 5 μM of PS during 270 minutes in the presence of a light fluence rate of 40 W.m-2 (reduction of 6 to 8 log). In the residual water, the inactivation of the 4 bacteria was also efficient and the decrease in bacterial number starts even sooner. It was observed a faster decrease in bacterial number when aPDT was combined with the addition of ampicillin and chloramphenicol at concentrations of 16 and 32 μg mL-1 (MIC dose 32 μg mL-1 for both antibiotics). The efficiency of aPDT with a lower porphyrin concentration (2.5 μM) in the presence of antibiotics at MIC dose was not significantly different of that obtained when just the PS was used. The addition of SDS did not affect the efficiency of aPDT. The results of this study showed that aPDT inactivate efficiently multidrug-resistant bacteria, in hospital residual water the bacterial inactivation is faster than in PBS, the combination of antibiotics and aPDT acts more efficiently than the aPDT alone, but aPDT in the presence of SDS does not affect the efficiency of bacterial inactivation. In conclusion, aPDT is effective to combating microbial diseases transmitted by multidrug-resistant bacteria and can be used to increase the efficacy of classical antibiotics.
O desenvolvimento de agentes antimicrobianos levou a pensar que as doenças provocadas por microrganismos diminuiriam, tornando-se insignificantes para a saúde humana. No entanto, a grande quantidade de antibióticos utilizados na medicina humana e veterinária levaram a uma selecção de bactérias patogénicas resistentes a muitos antibióticos, sendo os efluentes hospitalares uma das fontes mais importantes de organismos resistentes a antibióticos e de genes de resistência a antibióticos que são lançados no meio ambiente. O aumento significativo no desenvolvimento de diversos mecanismos de resistência a antibióticos provocou um aumento na pesquisa de tratamentos alternativos que apresentem baixo custo e que não apresentem efeitos adversos para o homem. A terapia fotodinâmica antimicrobiana (aPDT) alternativa aos antibióticos para o tratamento de doenças, visto que inactiva eficientemente microrganismos, é barata e segura. O objectivo geral deste trabalho foi avaliar a inactivação de quatro isolados clínicos de bactérias multirresistentes pela aPDT, utilizando uma porfirina tetracatiónica (PS). A eficácia da aPDT foi avaliada em solução tampão (PBS) e em águas residuais hospitalares para cada bactéria isolada e para a mistura das 4 bactérias juntas. O efeito sinergético da aPDT e antibióticos (ampicilina e cloranfenicol) também foi avaliado, assim como o efeito do dodecilsulfato de sódio (SDS) sobre a eficiência da aPDT. Os resultados mostram uma inactivação eficiente de bactérias multirresistentes em PBS utilizando 5 μM de PS, durante 270 minutos na presença de 40 W.m-2 de luz (redução de 6-8 log). Na água residual hospitalar, a inactivação das 4 bactérias foi igualmente eficiente, começado mesmo a diminuição do número de bactérias mais cedo que em PBS. Foi observado uma redução mais acentuada no número de bactérias quando a aPDT foi combinada com a adição de ampicilina e cloranfenicol nas concentrações de 16 e 32 μg mL-1 (dose MIC de 32 μg mL-1 para ambos os antibióticos). A eficiência da aPDT com uma concentração inferior de PS (2.5 μM) na presença de antibióticos na dose MIC não foi significativamente diferente da obtida quando foi utilizado apenas a porfirina. A adição do SDS também não afectou a eficiência da aPDT. Os resultados deste estudo mostraram que a aPDT inactiva bactérias multirresistentes de forma eficiente; em água de esgoto hospitalar a inactivação bacteriana é mais rápida do que em PBS, a combinação de antibióticos e aPDT actua de forma mais eficiente do que a APDT sozinha, mas eficiência da aPDT na presença de SDS não é afectada. Em conclusão, aPDT é eficaz para combater doenças microbianas transmitidas por bactérias multi-resistentes e podem ser usados para aumentar a eficácia dos antibióticos clássicos.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Bacteria in cancer therapy"

1

Hoffman, Robert M., ed. Bacterial Therapy of Cancer. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3515-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Arsenio, Fialho, and Chakrabarty Ananda M. 1938-, eds. Emerging cancer therapy: Microbial approaches and biotechnological tools. Hoboken, N.J: Wiley, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

1915-, Crane John, ed. The cancer cure that worked: Fifty years of suppression. Toronto, Canada: Marcus Books, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lynes, Barry. The cancer cure that worked!: Fifty years of suppression. Toronto, Canada: Marcus Books, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Khan, Abdul Arif, ed. Bacteria and Cancer. Dordrecht: Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-2585-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Khan, Abdul Arif. Bacteria and Cancer. Dordrecht: Springer Netherlands, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Clark, Hulda Regehr. The cure for all cancers: Including over 100 case histories of persons cured : Plus two revolutionary electronic circuits, one to diagnose and monitor progress, the other to zap parasites and bacteria!. San Diego: New Century Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chowdhury, Sreyan. Engineered Bacteria for Cancer Immunotherapy. [New York, N.Y.?]: [publisher not identified], 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Beger, Hans G., Markus Büchler, Ralph A. Reisfeld, and Gregor Schulz, eds. Cancer Therapy. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73721-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

D’Alessandro, Natale, Enrico Mihich, Luciano Rausa, Haim Tapiero, and Thomas R. Tritton, eds. Cancer Therapy. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-84613-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Bacteria in cancer therapy"

1

Patyar, Sazal, Ajay Prakash, and Bikash Medhi. "Bacteria as a Therapeutic Approach in Cancer Therapy." In Bacteria and Cancer, 185–208. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-2585-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sarotra, Pooja, and Bikash Medhi. "Use of Bacteria in Cancer Therapy." In Recent Results in Cancer Research, 111–21. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-42934-2_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mishra, Archana, and Vibhay Nath Tripathi. "Role of Bacteria in the Development of Cancer." In Colon Cancer Diagnosis and Therapy, 91–108. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-64668-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kumar, Pawan, Chitra Latka, and Bhupesh Taneja. "Current Antifungal Therapy and Drug Resistance Mechanisms in Dermatophytes." In Drug Resistance in Bacteria, Fungi, Malaria, and Cancer, 371–85. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48683-3_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mego, Michal, Sona Ciernikova, Martin Razus, Lubos Drgona, and Vladimir Zajac. "Probiotic Bacteria in Patients Treated with Chemotherapy and Radiation Therapy." In Critical Dietary Factors in Cancer Chemoprevention, 353–73. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-21461-0_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Traore, Mahama A., Ali Sahari, and Bahareh Behkam. "Construction of Bacteria-Based Cargo Carriers for Targeted Cancer Therapy." In Targeted Drug Delivery, 25–35. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kamble, Swapnil C., Farhan F. Shaikh, and Joyita Sarkar. "The Evolving Role of Nanoparticles in Bacteria Mediated Cancer Therapy." In Nanotechnology for Advances in Medical Microbiology, 331–47. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-9916-3_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jia, Li-Jun, and Zi-Chun Hua. "Development of Bacterial Vectors for Tumor-Targeted Gene Therapy." In Gene Therapy of Cancer, 131–54. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-561-9_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hoffman, Robert M. "Future of Bacterial Therapy of Cancer." In Methods in Molecular Biology, 177–84. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3515-4_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Leschner, Sara, and Siegfried Weiss. "Noninvasive In Vivo Imaging to Follow Bacteria Engaged in Cancer Therapy." In Methods in Molecular Biology, 61–68. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3515-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Bacteria in cancer therapy"

1

Lee, Wonjun, Jiin Park, Dongil Kang, and Seungbeum Suh. "Reconstituting Fundamentals of Bacteria Mediated Cancer Therapy On A Chip." In 2023 IEEE 36th International Conference on Micro Electro Mechanical Systems (MEMS). IEEE, 2023. http://dx.doi.org/10.1109/mems49605.2023.10052432.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kuo, Wen-Shuo, Ching-Ming Wu, and Chen-Sheng Yeh. "Bacteria-Assisted Photothermal Therapy in Cancers Cells." In 2007 Digest of papers Microprocesses and Nanotechnology. IEEE, 2007. http://dx.doi.org/10.1109/imnc.2007.4456189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lin, Yu-Hsin, Chih-Ho Lai, Yu-An Chen, Yi-Ru Lai, Ho Lin, and Jer-Tsong Hsieh. "Novel bacterial genotoxin-loaded nanoparticles for targeting therapy of radioresistant prostate cancer." In The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/iecc2021-09230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bogush, Ya Yu, and N. V. Ikonnikova. "OVERVIEW OF THE PROPERTIES OF BACTERIOPHAGES AND THE POSSIBILITIES OF PHAGE THERAPY IN THE MODERN WORLD." In SAKHAROV READINGS 2022: ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute of Belarusian State University, 2022. http://dx.doi.org/10.46646/sakh-2022-2-104-107.

Full text
Abstract:
Bacteriophages are bacterial viruses. They have strict specificity, the direction of action and, unlike antibiotics, do not suppress the development of normal microflora, without weakening the immune defense of the human body, do not contribute to allergization. Phage therapy has found wide application in practical healthcare in many countries of the world. Bacteriophages act as an alternative to generally accepted methods of treating bacterial infections. At the same time, the absence of any toxicity of drugs was established and their use was shown for any category of patients: children, pregnant women, the elderly, cancer patients, with postoperative complications, with diseases of the cardiovascular system and diabetes mellitus.
APA, Harvard, Vancouver, ISO, and other styles
5

Ackerley, David F., Janine N. Copp, Elsie M. Williams, Alexandra M. Mowday, Christopher P. Guise, Gareth A. Prosser, Sophie P. Syddall, Jeff B. Smaill, and Adam V. Patterson. "Abstract B88: Discovery, characterization, and engineering of bacterial nitroreductases for gene-directed enzyme prodrug therapy." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-b88.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rodiansyah, Achmad, Marselina Irasonia Tan, and Husna Nugrahapraja. "Construction, Cloning, and Overexpression of Staphylococcal Enterotoxin B Gene Synthetic (SEBsyn) in pET-28a(+): Pre-development Bacterial-Toxin Therapy for Cancer." In 7th International Conference on Biological Science (ICBS 2021). Paris, France: Atlantis Press, 2022. http://dx.doi.org/10.2991/absr.k.220406.065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Abreu, Thiago Martins de, Arthur Gomes Pidde, Pedro Henrique de Ávila Perillo, Silvaleide Ataides Assunção, Ianca Leandra Santos, and Débora Sara de Almeida Cardoso. "DELAY IN THE DIAGNOSIS OF INVASIVE DUCTAL CARCINOMA DUE TO AN INFECTIOUS MASTITIS: CASE REPORT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2067.

Full text
Abstract:
Introduction: Breast cancer is the most common cause among women, with invasive ductal carcinoma (ICD) being the most prevalent and having great phenotypic and genotypic heterogeneity and the ability to metastasize. In turn, mastitis is an inflammation in the breast region, infectious or noninfectious causes, most commonly affecting lactating women. Objectives: It is intended to report a case of ICD accompanied by infectious mastitis and its reverberations. Case Report: A 27-year-old woman presents with a clinical history of mastitis in her left breast that occurred about 3 months ago after weaning her son. She also explained about the use of antibiotic therapy, multiple previous drainages, and local complication with engorgement, edema, erythema, and purulent drainage in the surgical ostium of the left breast. A new drainage and material collection was carried out. Computed tomography of the chest indicated a solid heterogeneous lesion, dense, irregular contours, with areas of air trapping, liquefaction, and cleavage plane with the left pectoralis major muscle and ipsilateral axillary adenomegaly. Pathological pathology confirmed the hypothesis of neoplasia, indicating grade III ICD in comedonecrosis. Immunohistochemistry demonstrated triple-negative character and culture, positivity for Corynebacterium renale. She started neoadjuvant chemotherapy with reduced breast volume and absence of secretion today. Discussion: This is a common and problematic situation in health systems. Repeated outpatient referrals, invasive processes without resolution, aggravating the patient’s case. Moreover, it is noted that mastitis has delayed the diagnosis of the neoplasm, which, depending on the delay, may result in a worse prognosis or a more aggressive or expensive treatment. Conclusion: The diagnostic investigation of neoplasms is of great importance in case of prolonged mastitis not responsive to treatment, due to the fact that many mastitides may come from neoplastic processes that generate the lesion, which can make this injured area conducive to bacterial proliferation.
APA, Harvard, Vancouver, ISO, and other styles
8

Pezo, Rossanna C., Andrea Eisen, Sonal Gandhi, Ellen Warner, Katarzyna Jerzak, Maureen Trudeau, and Arun Seth. "Abstract OT-09-04: Analysis of genomic alterations in cell free DNA and gut bacterial diversity in metastatic breast cancer (MBC) patients on endocrine therapy: A pilot study." In Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.sabcs20-ot-09-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Guerrero-Preston, Rafael E., James Robert White, Filipa Godoy-Vitorino, Herminio Gonzalez, Arnold Rodríguez-Hilario, Kelvin Navarro, Gustavo A. Miranda-Carboni, et al. "Abstract 1018: High-resolution microbiome profiling and genome wide arrays uncover bacteria driven alterations of oncogenic and immune pathways in head and neck cancer patients treated with surgery, chemo-radiation and PD-1 checkpoint blockade therapy." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-1018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kang, Simook, and Baek-Il Kim. "The susceptibility of oral bacteria to antibacterial photodynamic therapy." In Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2019, edited by Tianhong Dai, Mei X. Wu, and Jürgen Popp. SPIE, 2019. http://dx.doi.org/10.1117/12.2507675.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Bacteria in cancer therapy"

1

Clarke, Robert S. Endocrine Therapy of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2005. http://dx.doi.org/10.21236/ada443230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Clarke, Robert. Endocrine Therapy of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2008. http://dx.doi.org/10.21236/ada492475.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gallion, Holly. Advances in Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, June 2010. http://dx.doi.org/10.21236/ada535545.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gallion, Holly. Advances in Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, June 2009. http://dx.doi.org/10.21236/ada510052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ma, Hong. Advances In Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2011. http://dx.doi.org/10.21236/ada562073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lis, Darrell. Advances in Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2012. http://dx.doi.org/10.21236/ada573097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tung, Ching-Hsuan. Protease Mediated Anti-Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, August 2006. http://dx.doi.org/10.21236/ada458446.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Clarke, Robert. Endocrine Therapy of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2006. http://dx.doi.org/10.21236/ada463407.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Clarke, Robert. Endocrine Therapy of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2007. http://dx.doi.org/10.21236/ada472777.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pitha-Rowe, Paula Marie. Ribozyme-Mediated Breast Cancer Gene Therapy. Fort Belvoir, VA: Defense Technical Information Center, October 2000. http://dx.doi.org/10.21236/ada394199.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Bacteria in cancer therapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography